Effect of Growth Hormone Injection on the IVF/ICSI Outcome of Patients With Poor Ovarian Reserve.
Study Details
Study Description
Brief Summary
Declined fertility and ovarian reserve in older women are associated with lower density of Growth hormone (GH) receptors and dysregulation in GH secretion. GH can regulate the expression of growth hormone receptor and strengthen the function of mitochondria, which could improve the quality of the female oocyte. In this study, a prospective randomized control will be conducted to explore the effect of GH adjuvant therapy on clinical outcome of in vitro fertilization.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Eligible subjects will be randomly assigned into either the study groups (receive somatropin co-treatment) or the control group (without sopmatropin treatment). Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) for approximately 6 weeks, i.e. from the beginning of preceding menstruation cycle until the day of ovum pickup. Both groups will receive a similar common protocol for ovarian stimulation. In vitro fertilization with or without intracytoplasmic sperm injection will be performed according to semen parameters. All embryos will undergo culture for blastocyst and the obtained blastocysts will be vitrified for deferred frozen embryo transfer. The Blastocyst formation rate will be the primary outcome measure.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Growth Hormone group Growth Hormone pretreatment for 6 weeks before ovarian stimulation |
Drug: Polyethylene Glycol Recombinant Human Somatropin
Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
|
| No Intervention: Control group No pretreatment before ovarian stimulation |
Outcome Measures
Primary Outcome Measures
- Blastocyst formation rate [One year]
the number of blastocyst/ the total number of embryos underwent blastocyst culture ×100%
- Live birth rate [One year]
Secondary Outcome Measures
- Number of retrieved oocytes [One year]
- Number of high-score embryos [One year]
- total amount of Gn used [One year]
- total days of Gn administration [One year]
- clinical pregnancy rate [One year]
- Ongoing pregnancy rate [One year]
- E2 levels on triggering day [One year]
- Endometrial thickness on triggering day [One year]
Eligibility Criteria
Criteria
Inclusion Criteria:
- 1)Married women between 35-40 years old; 2) serum AMH< 1.2ng/ml, and basal FSH<20IU/L during the screening period or within 6 months; 3) 18kg/m2≤BMI<30kg/m2; 4) Previous ART cycles <3.
Exclusion Criteria:
- 1）Gynecological diseases that affect pregnancy outcomes, such as submucous uterine myoma, intramural uterine myoma≥4cm, Ovarian cyst≥4cm, endometriosis, Uterine malformation, Tuberculosis of reproductive system; 2) Spontaneous abortion≥3 times; 3) Chromosomal abnormalities (except polymorphism) in one or both spouses; 4) Patients with well-defined and uncontrolled endocrine, metabolic, and adrenal diseases, such as diabetes, thyroid disease, Cushing's syndrome; 5) Patients with malignant tumors; 6) Previous use of somatropin products.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Shandong University
- RenJi Hospital
- The Second Hospital of Hebei Medical University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PEG-rhGH